521 related articles for article (PubMed ID: 33978741)
21. In silico analysis of the wild-type and mutant-type of BRCA2 gene.
Li J; Ge R; Lu G; Cai Y; Teng Y; Fan Z; Liao L; Kong L; Zhang J; Wei T; Li Q; Long T; Yu H; Li J
J Transl Med; 2024 May; 22(1):484. PubMed ID: 38773604
[TBL] [Abstract][Full Text] [Related]
22. The BRCA2-interacting protein DSS1 is vital for DNA repair, recombination, and genome stability in Ustilago maydis.
Kojic M; Yang H; Kostrub CF; Pavletich NP; Holloman WK
Mol Cell; 2003 Oct; 12(4):1043-9. PubMed ID: 14580353
[TBL] [Abstract][Full Text] [Related]
23. The proteasome is involved in determining differential utilization of double-strand break repair pathways.
Gudmundsdottir K; Lord CJ; Ashworth A
Oncogene; 2007 Nov; 26(54):7601-6. PubMed ID: 17563742
[TBL] [Abstract][Full Text] [Related]
24. Functional assays for analysis of variants of uncertain significance in BRCA2.
Guidugli L; Carreira A; Caputo SM; Ehlen A; Galli A; Monteiro AN; Neuhausen SL; Hansen TV; Couch FJ; Vreeswijk MP;
Hum Mutat; 2014 Feb; 35(2):151-64. PubMed ID: 24323938
[TBL] [Abstract][Full Text] [Related]
25. DNA repair-related functional assays for the classification of BRCA1 and BRCA2 variants: a critical review and needs assessment.
Toland AE; Andreassen PR
J Med Genet; 2017 Nov; 54(11):721-731. PubMed ID: 28866612
[TBL] [Abstract][Full Text] [Related]
26. A cancer-associated BRCA2 mutation reveals masked nuclear export signals controlling localization.
Jeyasekharan AD; Liu Y; Hattori H; Pisupati V; Jonsdottir AB; Rajendra E; Lee M; Sundaramoorthy E; Schlachter S; Kaminski CF; Ofir-Rosenfeld Y; Sato K; Savill J; Ayoub N; Venkitaraman AR
Nat Struct Mol Biol; 2013 Oct; 20(10):1191-8. PubMed ID: 24013206
[TBL] [Abstract][Full Text] [Related]
27. Clinical and molecular characterization of the BRCA2 p.Asn3124Ile variant reveals substantial evidence for pathogenic significance.
Surowy HM; Sutter C; Mittnacht M; Klaes R; Schaefer D; Evers C; Burgemeister AL; Goehringer C; Dikow N; Heil J; Golatta M; Schott S; Schneeweiss A; Bugert P; Sohn C; Bartram CR; Burwinkel B
Breast Cancer Res Treat; 2014 Jun; 145(2):451-60. PubMed ID: 24728577
[TBL] [Abstract][Full Text] [Related]
28. Missense variants of uncertain significance (VUS) altering the phosphorylation patterns of BRCA1 and BRCA2.
Tram E; Savas S; Ozcelik H
PLoS One; 2013; 8(5):e62468. PubMed ID: 23704879
[TBL] [Abstract][Full Text] [Related]
29. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.
Alhuqail AJ; Alzahrani A; Almubarak H; Al-Qadheeb S; Alghofaili L; Almoghrabi N; Alhussaini H; Park BH; Colak D; Karakas B
Breast Cancer Res Treat; 2018 Apr; 168(3):695-702. PubMed ID: 29297111
[TBL] [Abstract][Full Text] [Related]
30. Expression and mutations of BRCA in breast cancer and ovarian cancer: Evidence from bioinformatics analyses.
Wang Z; Zhang J; Zhang Y; Deng Q; Liang H
Int J Mol Med; 2018 Dec; 42(6):3542-3550. PubMed ID: 30221688
[TBL] [Abstract][Full Text] [Related]
31. Functional assays for classification of BRCA2 variants of uncertain significance.
Farrugia DJ; Agarwal MK; Pankratz VS; Deffenbaugh AM; Pruss D; Frye C; Wadum L; Johnson K; Mentlick J; Tavtigian SV; Goldgar DE; Couch FJ
Cancer Res; 2008 May; 68(9):3523-31. PubMed ID: 18451181
[TBL] [Abstract][Full Text] [Related]
32. The biological effects and clinical implications of BRCA mutations: where do we go from here?
Stoppa-Lyonnet D
Eur J Hum Genet; 2016 Sep; 24 Suppl 1(Suppl 1):S3-9. PubMed ID: 27514841
[TBL] [Abstract][Full Text] [Related]
33. Functional evaluation of BRCA2 variants mapping to the PALB2-binding and C-terminal DNA-binding domains using a mouse ES cell-based assay.
Biswas K; Das R; Eggington JM; Qiao H; North SL; Stauffer S; Burkett SS; Martin BK; Southon E; Sizemore SC; Pruss D; Bowles KR; Roa BB; Hunter N; Tessarollo L; Wenstrup RJ; Byrd RA; Sharan SK
Hum Mol Genet; 2012 Sep; 21(18):3993-4006. PubMed ID: 22678057
[TBL] [Abstract][Full Text] [Related]
34. Assessment of the Clinical Relevance of BRCA2 Missense Variants by Functional and Computational Approaches.
Guidugli L; Shimelis H; Masica DL; Pankratz VS; Lipton GB; Singh N; Hu C; Monteiro ANA; Lindor NM; Goldgar DE; Karchin R; Iversen ES; Couch FJ
Am J Hum Genet; 2018 Feb; 102(2):233-248. PubMed ID: 29394989
[TBL] [Abstract][Full Text] [Related]
35. The carboxyl terminus of Brca2 links the disassembly of Rad51 complexes to mitotic entry.
Ayoub N; Rajendra E; Su X; Jeyasekharan AD; Mahen R; Venkitaraman AR
Curr Biol; 2009 Jul; 19(13):1075-85. PubMed ID: 19540122
[TBL] [Abstract][Full Text] [Related]
36. Novel germline BRCA1 and BRCA2 mutations in breast and breast/ovarian cancer families from the Czech Republic.
Machackova E; Damborsky J; Valik D; Foretova L
Hum Mutat; 2001 Dec; 18(6):545. PubMed ID: 11748848
[TBL] [Abstract][Full Text] [Related]
37. Characterization of BRCA1 and BRCA2 variants found in a Norwegian breast or ovarian cancer cohort.
Jarhelle E; Riise Stensland HM; Mæhle L; Van Ghelue M
Fam Cancer; 2017 Jan; 16(1):1-16. PubMed ID: 27495310
[TBL] [Abstract][Full Text] [Related]
38. Distinct roles of BRCA2 in replication fork protection in response to hydroxyurea and DNA interstrand cross-links.
Rickman KA; Noonan RJ; Lach FP; Sridhar S; Wang AT; Abhyankar A; Huang A; Kelly M; Auerbach AD; Smogorzewska A
Genes Dev; 2020 Jun; 34(11-12):832-846. PubMed ID: 32354836
[TBL] [Abstract][Full Text] [Related]
39. PALB2 links BRCA1 and BRCA2 in the DNA-damage response.
Zhang F; Ma J; Wu J; Ye L; Cai H; Xia B; Yu X
Curr Biol; 2009 Mar; 19(6):524-9. PubMed ID: 19268590
[TBL] [Abstract][Full Text] [Related]
40. Screening of 1331 Danish breast and/or ovarian cancer families identified 40 novel BRCA1 and BRCA2 mutations.
Hansen TV; Jønson L; Steffensen AY; Andersen MK; Kjaergaard S; Gerdes AM; Ejlertsen B; Nielsen FC
Fam Cancer; 2011 Jun; 10(2):207-12. PubMed ID: 21318380
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
